Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma

NCT07527325 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT07527325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07527325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
February 1, 2030
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)